These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16236428)

  • 1. Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development.
    Chassagnole C; Jackson RC; Hussain N; Bashir L; Derow C; Savin J; Fell DA
    Biosystems; 2006; 83(2-3):91-7. PubMed ID: 16236428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
    Ling H; Samarasinghe S; Kulasiri D
    Biosystems; 2013 Feb; 111(2):71-82. PubMed ID: 23254306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
    Baselga J; Mita AC; Schöffski P; Dumez H; Rojo F; Tabernero J; DiLea C; Mietlowski W; Low C; Huang J; Dugan M; Parker K; Walk E; van Oosterom A; Martinelli E; Takimoto CH
    Clin Cancer Res; 2012 Nov; 18(22):6364-72. PubMed ID: 23014528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a telomere destabilizing agent on cancer cell-cycle dynamics--integrated modelling and experiments.
    Hirt BV; Wattis JA; Preston SP; Laughton CA
    J Theor Biol; 2012 Feb; 295():9-22. PubMed ID: 22108242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.
    Schättler H; Ledzewicz U; Cardwell B
    Math Biosci Eng; 2011 Apr; 8(2):355-69. PubMed ID: 21631134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
    Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
    PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles.
    Sinek J; Frieboes H; Zheng X; Cristini V
    Biomed Microdevices; 2004 Dec; 6(4):297-309. PubMed ID: 15548877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
    Park IW; Reddy MV; Reddy EP; Groopman JE
    Oncogene; 2007 Aug; 26(38):5635-42. PubMed ID: 17369860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
    Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
    Poleszczuk J; Bodnar M; Foryś U
    Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model.
    Florian JA; Eiseman JL; Parker RS
    Comput Biol Med; 2008 Mar; 38(3):339-47. PubMed ID: 18222419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling recombinant immunotoxin efficacies in solid tumors.
    Chen KC; Kim J; Li X; Lee B
    Ann Biomed Eng; 2008 Mar; 36(3):486-512. PubMed ID: 18183487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.
    Ledzewicz U; Maurer H; Schättler H
    Math Biosci Eng; 2011 Apr; 8(2):307-23. PubMed ID: 21631132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.